Pub Date : 2025-10-15DOI: 10.1038/s41409-025-02732-w
Patryk Sobieralski, Tomasz Czerw, Luuk Gras, Linda Koster, Nicolaus Kröger, Thomas Schroeder, Lone Friis, Elisabetta Metafuni, Jakob Passweg, Marie Robin, Matthias Stelljes, Annoek E. C. Broers, Patrice Chevallier, Robert Zeiser, Marie Therese Rubio, Mareike Verbeek, Ipek Yonal-Hindilerden, Domenico Pastore, Jan Zaucha, Kavita Raj, Joanna Drozd-Sokołowska, Giorgia Battipaglia, Nicola Polverelli, Juan Carlos Hernández-Boluda, Donal P. McLornan
Outcomes in myelofibrosis (MF) patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) appear unaffected by the intensity of the preparative regimen, defined traditionally as myeloablative (MAC) or reduced intensity conditioning (RIC). The Transplant Conditioning Intensity (TCI) index is an objective tool offering a precise measure of conditioning intensity. We explored the potential association between TCI score and overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) in 2454 MF patients undergoing allo-HCT between 2012 and 2021, selected from the EBMT registry. Patients receiving TCI-intermediate/high regimens had similar OS (HR 1.12, 95% CI 0.97–1.30) and PFS (HR 1.00, 95% CI 0.88–1.14) compared to TCI-low regimens. However, TCI-intermediate/high regimens were associated with lower risk of relapse (HR 0.74, 95% CI 0.61–0.91, p = 0.008) and higher risk of NRM (HR 1.24, 95% CI 1.04–1.48, p = 0.02). Our findings suggest that the TCI score provides a more clinically relevant stratification of conditioning intensity than the conventional MAC/RIC classification. While higher intensity TCI regimens are associated with lower RI, this benefit is offset by increased NRM, resulting in no survival advantage. However, the TCI index may enable a more personalized approach to conditioning regimen selection by balancing relapse risk with patient frailty.
骨髓纤维化（MF）患者接受同种异体造血细胞移植（allogenic hematopoietic cell transplantation, alloo - hct）的结果似乎不受预备方案强度的影响，传统上定义为骨髓清除（MAC）或降低强度调节（RIC）。移植调节强度（TCI）指数是提供调节强度精确测量的客观工具。我们从EBMT注册表中选择了2454例2012年至2021年间接受异位肝移植的MF患者，探讨了TCI评分与总生存期（OS）、无进展生存期（PFS）、累积复发发生率（CIR）和非复发死亡率（NRM）之间的潜在关联。与低tci方案相比，接受tci中高方案的患者具有相似的OS （HR 1.12, 95% CI 0.97-1.30）和PFS （HR 1.00, 95% CI 0.88-1.14）。然而，tci -中/高方案与较低的复发风险（HR 0.74, 95% CI 0.61-0.91, p = 0.008）和较高的NRM风险（HR 1.24, 95% CI 1.04-1.48, p = 0.02）相关。我们的研究结果表明，与传统的MAC/RIC分类相比，TCI评分提供了更具有临床相关性的调节强度分层。虽然高强度TCI方案与较低的RI相关，但这种益处被增加的NRM抵消，导致没有生存优势。然而，TCI指数可以通过平衡复发风险和患者虚弱来实现更个性化的治疗方案选择。
{"title":"Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT","authors":"Patryk Sobieralski, Tomasz Czerw, Luuk Gras, Linda Koster, Nicolaus Kröger, Thomas Schroeder, Lone Friis, Elisabetta Metafuni, Jakob Passweg, Marie Robin, Matthias Stelljes, Annoek E. C. Broers, Patrice Chevallier, Robert Zeiser, Marie Therese Rubio, Mareike Verbeek, Ipek Yonal-Hindilerden, Domenico Pastore, Jan Zaucha, Kavita Raj, Joanna Drozd-Sokołowska, Giorgia Battipaglia, Nicola Polverelli, Juan Carlos Hernández-Boluda, Donal P. McLornan","doi":"10.1038/s41409-025-02732-w","DOIUrl":"10.1038/s41409-025-02732-w","url":null,"abstract":"Outcomes in myelofibrosis (MF) patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) appear unaffected by the intensity of the preparative regimen, defined traditionally as myeloablative (MAC) or reduced intensity conditioning (RIC). The Transplant Conditioning Intensity (TCI) index is an objective tool offering a precise measure of conditioning intensity. We explored the potential association between TCI score and overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) in 2454 MF patients undergoing allo-HCT between 2012 and 2021, selected from the EBMT registry. Patients receiving TCI-intermediate/high regimens had similar OS (HR 1.12, 95% CI 0.97–1.30) and PFS (HR 1.00, 95% CI 0.88–1.14) compared to TCI-low regimens. However, TCI-intermediate/high regimens were associated with lower risk of relapse (HR 0.74, 95% CI 0.61–0.91, p = 0.008) and higher risk of NRM (HR 1.24, 95% CI 1.04–1.48, p = 0.02). Our findings suggest that the TCI score provides a more clinically relevant stratification of conditioning intensity than the conventional MAC/RIC classification. While higher intensity TCI regimens are associated with lower RI, this benefit is offset by increased NRM, resulting in no survival advantage. However, the TCI index may enable a more personalized approach to conditioning regimen selection by balancing relapse risk with patient frailty.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 1","pages":"36-43"},"PeriodicalIF":5.2,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.comhttps://www.nature.com/articles/s41409-025-02732-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145298500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-13DOI: 10.1038/s41409-025-02733-9
James Fan Wu, Noel Estrada-Merly, Yuhong Zhou, Bethany Canales, Tina W. F. Yen, Anita D’Souza
{"title":"Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability","authors":"James Fan Wu, Noel Estrada-Merly, Yuhong Zhou, Bethany Canales, Tina W. F. Yen, Anita D’Souza","doi":"10.1038/s41409-025-02733-9","DOIUrl":"10.1038/s41409-025-02733-9","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 1","pages":"95-97"},"PeriodicalIF":5.2,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12590446/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-06DOI: 10.1038/s41409-025-02731-x
M. J. M. Janssen, M. A. de Witte, L.G.M. Daenen, F. Verduyn Lunell, D. van Baarle, J. Kuball, A.H.W. Bruns
{"title":"Preserved measles immunity after allogeneic hematopoietic stem cell transplantation in a cohort of mainly αβ T-cell-depleted graft recipients","authors":"M. J. M. Janssen, M. A. de Witte, L.G.M. Daenen, F. Verduyn Lunell, D. van Baarle, J. Kuball, A.H.W. Bruns","doi":"10.1038/s41409-025-02731-x","DOIUrl":"10.1038/s41409-025-02731-x","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 1","pages":"92-94"},"PeriodicalIF":5.2,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-06DOI: 10.1038/s41409-025-02728-6
Liang-Piu Koh, Yeh Ching Linn, Yang Liang Boo, Victor Ling, Zi Yi Lim, Michelle Poon, Jeffrey Quek, Hein Than, Colin Phipps Diong, Balamurugan Vellayappan, Aloysius Ho, Francesca Lim, William Hwang, Lip Kun Tan, Jean Rachel M. Catapia, Joanne Lee, Ian Wu, Kheng Wei Yeoh, Bryan Ho, Wen Shen Looi, Lawrence Ng, Tertius Tansloan Tuy, Yvonne Loh, Teck Guan Soh, Gina Gan, Kee Khiang Heng, Yin Jie Koh, Wing Leung
In haploidentical hematopoietic cell transplantation (Haplo-HCT), in vivo or ex vivo T-cell depletion (TCD) can prevent graft-versus-host disease (GVHD) but increase risk of infection and relapse. We hypothesized that TCRαβ-depleted allograft together with upfront infusion with CD45RA-depleted memory T cells (αβTCD + TMDLI) may result in favourable GVHD-free and relapse-free survival (GRFS). Between January 2017 and July 2023, 145 adult patients with various haematological malignancies received αβTCD + TMDLI. All except 2 patients had robust engraftment at a median of 12 days for neutrophil and 11 days for platelet. The cumulative incidence (CI) of CMV, EBV, HHV6 or ADV infection was only 43% (n = 63) at day+120. CI of grade II–IV and III–IV acute GVHD at 180 days was 31% and 8% respectively. Chronic GVHD was seen in only 5 patients with a 2-year CI of 4%. CI of non-relapse mortality and relapse at 2 years were 17% and 22% respectively. At a median follow up of 28 months, 3-year overall (OS), event-free (EFS), and GRFS were 67%, 62%, and 59%, respectively. This was significantly improved over a propensity score-matched contemporary cohort (n = 53) who received PTCy as GVHD prophylaxis. This first multi-center study demonstrated the potential benefits of the αβTCD + TMDLI approach for Haplo-HCT.
{"title":"Upfront memory T cell add-back with haploidentical TCRαβ-depleted graft in adults with haematological malignancies: a nationwide, multicentre, single-arm, prospective study","authors":"Liang-Piu Koh, Yeh Ching Linn, Yang Liang Boo, Victor Ling, Zi Yi Lim, Michelle Poon, Jeffrey Quek, Hein Than, Colin Phipps Diong, Balamurugan Vellayappan, Aloysius Ho, Francesca Lim, William Hwang, Lip Kun Tan, Jean Rachel M. Catapia, Joanne Lee, Ian Wu, Kheng Wei Yeoh, Bryan Ho, Wen Shen Looi, Lawrence Ng, Tertius Tansloan Tuy, Yvonne Loh, Teck Guan Soh, Gina Gan, Kee Khiang Heng, Yin Jie Koh, Wing Leung","doi":"10.1038/s41409-025-02728-6","DOIUrl":"10.1038/s41409-025-02728-6","url":null,"abstract":"In haploidentical hematopoietic cell transplantation (Haplo-HCT), in vivo or ex vivo T-cell depletion (TCD) can prevent graft-versus-host disease (GVHD) but increase risk of infection and relapse. We hypothesized that TCRαβ-depleted allograft together with upfront infusion with CD45RA-depleted memory T cells (αβTCD + TMDLI) may result in favourable GVHD-free and relapse-free survival (GRFS). Between January 2017 and July 2023, 145 adult patients with various haematological malignancies received αβTCD + TMDLI. All except 2 patients had robust engraftment at a median of 12 days for neutrophil and 11 days for platelet. The cumulative incidence (CI) of CMV, EBV, HHV6 or ADV infection was only 43% (n = 63) at day+120. CI of grade II–IV and III–IV acute GVHD at 180 days was 31% and 8% respectively. Chronic GVHD was seen in only 5 patients with a 2-year CI of 4%. CI of non-relapse mortality and relapse at 2 years were 17% and 22% respectively. At a median follow up of 28 months, 3-year overall (OS), event-free (EFS), and GRFS were 67%, 62%, and 59%, respectively. This was significantly improved over a propensity score-matched contemporary cohort (n = 53) who received PTCy as GVHD prophylaxis. This first multi-center study demonstrated the potential benefits of the αβTCD + TMDLI approach for Haplo-HCT.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 1","pages":"26-35"},"PeriodicalIF":5.2,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Choosing an optimal alternative donor is an important clinical concern in allogeneic hematopoietic cell transplantation (HCT). In Japan, single-unit umbilical cord blood transplantation (UCBT) has been widely used in the last two decades, whereas HCT from HLA-haploidentical related donors (haplo-HCT) has been increasingly used following the advent of posttransplant cyclophosphamide (PTCY) for graft-versus-host disease (GVHD) prophylaxis. This registry-based study aimed to compare outcomes between single-unit UCBT (n = 848) and PTCY-based haplo-HCT (n = 241) performed during first complete remission in patients with acute myeloid leukemia. UCBT was associated with a lower likelihood of engraftment (P < 0.001), a higher risk of grade 2–4 and grade 3–4 acute GVHD (P = 0.003 each), and a lower risk of extensive chronic GVHD (P = 0.048). The UCBT and haplo-HCT groups did not significantly differ in 3-year probabilities of overall survival (68% versus 69%, P = 0.686), GVHD/relapse-free survival (55% versus 54%, P = 0.866), relapse (14% versus 16%, P = 0.463), and non-relapse mortality (21% versus 19%, P = 0.403), respectively, which were confirmed with multivariate analysis. These results indicate that both procedures should be considered viable options for patients lacking a matched donor.
{"title":"Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia","authors":"Masamitsu Yanada, Satoshi Yamasaki, Shohei Mizuno, Junichi Sugita, Takahiro Fujino, Yukiko Misaki, Masatsugu Tanaka, Naoyuki Uchida, Makoto Onizuka, Noriko Doki, Shuichi Ota, Masashi Sawa, Toshiro Kawakita, Yuta Hasegawa, Hirohisa Nakamae, Kazuya Ishiwata, Nobuhiro Hiramoto, Fumihiko Ishimaru, Junya Kanda, Marie Ohbiki, Yoshiko Atsuta, Hideki Nakasone, Takaaki Konuma","doi":"10.1038/s41409-025-02729-5","DOIUrl":"10.1038/s41409-025-02729-5","url":null,"abstract":"Choosing an optimal alternative donor is an important clinical concern in allogeneic hematopoietic cell transplantation (HCT). In Japan, single-unit umbilical cord blood transplantation (UCBT) has been widely used in the last two decades, whereas HCT from HLA-haploidentical related donors (haplo-HCT) has been increasingly used following the advent of posttransplant cyclophosphamide (PTCY) for graft-versus-host disease (GVHD) prophylaxis. This registry-based study aimed to compare outcomes between single-unit UCBT (n = 848) and PTCY-based haplo-HCT (n = 241) performed during first complete remission in patients with acute myeloid leukemia. UCBT was associated with a lower likelihood of engraftment (P < 0.001), a higher risk of grade 2–4 and grade 3–4 acute GVHD (P = 0.003 each), and a lower risk of extensive chronic GVHD (P = 0.048). The UCBT and haplo-HCT groups did not significantly differ in 3-year probabilities of overall survival (68% versus 69%, P = 0.686), GVHD/relapse-free survival (55% versus 54%, P = 0.866), relapse (14% versus 16%, P = 0.463), and non-relapse mortality (21% versus 19%, P = 0.403), respectively, which were confirmed with multivariate analysis. These results indicate that both procedures should be considered viable options for patients lacking a matched donor.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"61 1","pages":"18-25"},"PeriodicalIF":5.2,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-04DOI: 10.1038/s41409-025-02721-z
Gagan Raju, Moneeza Walji, David Nemirovsky, Sean Devlin, Ilan Goldstein, Amandeep Singh, Pamela Susman, Natasia Rodriguez, Miguel-Angel Perales, Doris M. Ponce
Belumosudil is approved after failure of ≥2 lines of therapy in chronic graft-versus-host disease cGVHD. However, real-world data is limited. We conducted a retrospective analysis of 67 patients with steroid-refractory or dependent (SR/SD) cGVHD. At baseline, most patients had advanced multi-organ cGVHD. The 6- and 12-month overall response rate (ORR) was 61%. However, a subset of patients achieved deeper responses with ongoing therapy at 12 months. The 6-month failure-free survival (FFS) was 75% (95%CI: 65–86) whereas the 12-month FFS was 66% (95%CI: 55–78). A low incidence of drug-related grade ≥3 toxicities was observed. A cohort of patients with immune function analysis showed gradual improvement in immune subsets at 1-year post-treatment. The combined bel-rux cohort (n = 14) showed a 6- and 12-month ORR of 64% and 57%, respectively. Overall, belumosudil was associated with high treatment response and survival outcomes. Notably, deeper responses were observed with ongoing therapy, and it was overall well tolerated. In a cohort of patients, immune cell populations had preserved to improved values throughout treatment. Patients who received bel-rux demonstrated efficacy and safety as well. Overall, our real-world study indicates similar findings to the clinical trial and supports the use of belumosudil in cGVHD.
{"title":"Real-world experience of belumosudil and belumosudil/ruxolitinib combination in steroid-refractory chronic graft-versus-host disease","authors":"Gagan Raju, Moneeza Walji, David Nemirovsky, Sean Devlin, Ilan Goldstein, Amandeep Singh, Pamela Susman, Natasia Rodriguez, Miguel-Angel Perales, Doris M. Ponce","doi":"10.1038/s41409-025-02721-z","DOIUrl":"10.1038/s41409-025-02721-z","url":null,"abstract":"Belumosudil is approved after failure of ≥2 lines of therapy in chronic graft-versus-host disease cGVHD. However, real-world data is limited. We conducted a retrospective analysis of 67 patients with steroid-refractory or dependent (SR/SD) cGVHD. At baseline, most patients had advanced multi-organ cGVHD. The 6- and 12-month overall response rate (ORR) was 61%. However, a subset of patients achieved deeper responses with ongoing therapy at 12 months. The 6-month failure-free survival (FFS) was 75% (95%CI: 65–86) whereas the 12-month FFS was 66% (95%CI: 55–78). A low incidence of drug-related grade ≥3 toxicities was observed. A cohort of patients with immune function analysis showed gradual improvement in immune subsets at 1-year post-treatment. The combined bel-rux cohort (n = 14) showed a 6- and 12-month ORR of 64% and 57%, respectively. Overall, belumosudil was associated with high treatment response and survival outcomes. Notably, deeper responses were observed with ongoing therapy, and it was overall well tolerated. In a cohort of patients, immune cell populations had preserved to improved values throughout treatment. Patients who received bel-rux demonstrated efficacy and safety as well. Overall, our real-world study indicates similar findings to the clinical trial and supports the use of belumosudil in cGVHD.","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 12","pages":"1649-1656"},"PeriodicalIF":5.2,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145228457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02647-6
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards.","authors":"","doi":"10.1038/s41409-025-02647-6","DOIUrl":"https://doi.org/10.1038/s41409-025-02647-6","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"6-8"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145451032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02645-8
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising committee.","authors":"","doi":"10.1038/s41409-025-02645-8","DOIUrl":"https://doi.org/10.1038/s41409-025-02645-8","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"2-3"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-01DOI: 10.1038/s41409-025-02651-w
{"title":"The 51<sup>st</sup> Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Poster Session (P001-P909).","authors":"","doi":"10.1038/s41409-025-02651-w","DOIUrl":"https://doi.org/10.1038/s41409-025-02651-w","url":null,"abstract":"","PeriodicalId":9126,"journal":{"name":"Bone Marrow Transplantation","volume":"60 Suppl 1","pages":"183-887"},"PeriodicalIF":5.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145450991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：